Emergency contraception For emergency contraception a 30 mg tablet is used within 120 hours (5 days) after unprotected intercourse or contraceptive failure. It has been shown to prevent about 62–85% of expected pregnancies, and prevents more pregnancies than emergency contraception with levonorgestrel.<unk>  is available by prescription for emergency contraception in over 50 countries, with access through pharmacists without a prescription being tested in the United Kingdom. In November 2014, the European Medicines Agency (EMA) recommended availability of ellaOne emergency contraceptive without prescription in the European Union. In January 2015 the European Commission issued an implementing decision amending accordingly the marketing authorization of EllaOne in the EU. Since July 2016, it is available without prescription in Israel. Uterine fibroids<unk>  is used for pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. The use of<unk>  to treat fibroids was suspended in the European Union in March 2020. In November 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended that<unk>  be used only to treat uterine fibroids in premenopausal women for whom surgical procedures (including uterine fibroid embolization) are not appropriate or have not worked. In addition, the committee stated that<unk>  must not be used for controlling symptoms of uterine fibroids while awaiting surgical treatment. Treatment of uterine fibroids with<unk>  for 13 weeks effectively controlled excessive bleeding due to uterine fibroids and reduced the size of the fibroids. Two intermittent 3-months treatment courses of<unk>  10 mg resulted in amenorrhea at the end of the first treatment course in 79.5%, at the end of the second course in 88.5% of subjects. Mean myoma volume reduction observed during the first treatment course (−41.9%) was maintained during the second one (−43.7%). After two to four 3-months courses of treatment, UPA-treated fibroids shown about -70% in volume reduction. Volume reduction of uterine fibroid induced by<unk>  was tentatively explained by the combination of multifactorial events involving control of proliferation of the tumor cells, induction of apoptosis and remodeling of the extracellular matrix under the action of matrix metalloproteinases. In May 2018, the European Medicines Agency (EMA) recommended measures to minimize the risk of rare but serious liver injury with<unk> , including contraindication in women with known liver problems; liver tests before, during and after stopping treatment; a card for people to inform them about the need for liver monitoring and to contact their doctor should they develop symptoms of liver injury. In addition, use of the medicine for more than one treatment course has been restricted to women who are not eligible for surgery.
Ulipristal acetate
Macimorelin
Linagliptin
Saxagliptin
Sitagliptin
Liraglutide
Vildagliptin
Lumacaftor